Mindprint implements market-leading automation solution for Ockham Oncology

Mindprint Inc. and Ockham Development, Inc. have implemented an innovative automation software system to help the global CRO manage trials efficiently to ensure a more focused approach to its core oncology mission.

Mindprint, a Toronto-based company specializing in software management solutions for the Contract Research industry, has worked onsite with Ockham to customize the new management tool, which went live in December 2013.

"Our passion is helping companies fight cancer," said Jim Baker, CEO of Ockham, which includes a global division solely focused on cancer drug trials. "We have successfully completed more than 250 oncology trials for some of the leading pharma companies.

"Because of the operational complexity in managing global trials, our conventional software tools have become cumbersome. After extensive research, we chose Mindprint as our solution."

Ockham continues to experience fast growth just two years after the successful integration of Nexus Oncology a Scotland-based oncology CRO. Mindprint, which specializes in CRO software solutions, prepared an operational plan while working closely with the Ockham team.

"We interviewed the key subject matter experts for Ockham Oncology," said Prasad A. Sristi, CEO of Mindprint."We were able to use our library of CRO solutions for demo purposes to gather quality feedback and build consensus about what Ockham needed." Both Sristi and Baker praised the thorough review of Ockham's business.

"These new tools help us serve our clients more effectively and preserve our essential focus on the clinical challenge in helping our clients in developing new cancer-fighting formulations," Baker said.

Mindprint implemented a professional services automation (PSA) tool customized for Ockham's needs. A key part of the PSA allows Ockham to measure the profitability of each clinical study - a challenging aspect of every trial due to the many data sources associated with each trial.

Sristi said the core of the technology is the patented Axpert platform developed in Bangalore by India-based Agile Labs. This tool allow the customization of enterprise management systems without extensive hard coding.

Baker praised Mindprint software's capacity to do much more for their business in addition to generating interactive reports on profitability. "The system implemented by Mindprint is exactly what we needed," Baker said. "When we began implementation, we realized that if utilized correctly Mindprint can be fundamental to our business and meet our growth demands."

The new software tools allow "much more accurate financial data and financial forecasts for our entire company," Baker said.

About Ockham
Launched in 1986, Ockham is a global oncology CRO and full-spectrum global resourcing company. Clinical expertise, therapeutic focus, and successful oncology trial outcomes have created an industry leadership position for Ockham Oncology. Ockham Source continues to achieve sustained success by offering traditional sourcing solutions as well as a growing FSP (Functional Service Provider). Ockham’s world headquarters is based in Cary, North Carolina, with the European headquarters located in Roslin, Scotland, near Edinburgh. Ockham offices are located strategically around the world to serve global customers.

About Mindprint
Mindprint Inc. specializes in serving Contract Research Organizations and pharmaceutical companies with cloud-based enterprise software solutions that provide direct business benefits such as enhanced profitability, streamlined business processes and superior customer value. Launched in 2009 and headquartered in Markham, Ontario, Mindprint has partnered with a number of leading CROs and understands the life cycle of a clinical study as well as the business challenges and system requirements unique to the life sciences industry. Mindprint's library of CRO modules, based on the Axpert enterprise resource planning platform enables rapid custom software development without expensive coding. Read more about Mindprint Inc.

Most Popular Now

Novo Nordisk announces plans to transform its appr…

Novo Nordisk announced plans to restructure its Research & Development (R&D) organisation to accelerate the expansion and diversification of its pipeline across serious c...

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Sat...

World's largest Alzheimer's survey reveals most ad…

Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), announced results from the largest glob...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Discovery could explain failed clinical trials for…

Researchers at King's College London have discovered a vicious feedback loop underlying brain degeneration in Alzheimer's disease which may explain why so many drug trial...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

Aspirin found not to prolong healthy aging

Taking a low-dose aspirin daily does not prolong healthy living in older adults, according to findings from the ASPirin in Reducing Events in the Elderly (ASPREE) trial p...

The Lancet Respiratory Medicine publishes first Ph…

AstraZeneca today announced publication of results from the KRONOS Phase III trial which evaluated the efficacy and safety of triple combination therapy PT010 (budesonide...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

Clinical gene discovery program solves 30 medical …

A table in a recently published paper tells the story of 30 families who have, sometimes after years of searching, finally received an answer about the condition that has...